AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.61 |
Market Cap | 17.96M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -3.67 |
PE Ratio (ttm) | -0.51 |
Forward PE | n/a |
Analyst | Hold |
Ask | 1.9 |
Volume | 226,438 |
Avg. Volume (20D) | 122,480 |
Open | 1.81 |
Previous Close | 1.78 |
Day's Range | 1.72 - 1.91 |
52-Week Range | 1.72 - 10.50 |
Beta | undefined |
About HOOK
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-2...
Analyst Forecast
According to 3 analyst ratings, the average rating for HOOK stock is "Hold." The 12-month stock price forecast is $4.5, which is an increase of 141.94% from the latest price.
Next Earnings Release
Analysts project revenue of $6.25M, reflecting a -15.62% YoY shrinking and earnings per share of -1.41, making a -35.91% decrease YoY.
1 week ago · proactiveinvestors.co.uk
Gilead backs proposed Poolbeg Pharma's proposed tie-up with HOOKIPAGilead Sciences Inc (NASDAQ:GILD, ETR:GIS), the largest shareholder in HOOKIPA Pharma, has thrown its backing behind the proposed merger with Poolbeg Pharma PLC (AIM:POLB). Gilead, which holds just un...